Secretin-enhanced Magnetic Resonance Cholangiopancreatography in Pancreatic Insufficient and Pancreatic Sufficient Cystic Fibrosis Patients

Authors

  • Katarzyna Jonczyk-Potoczna Department of Pediatric Radiology, Poznan University of Medical Sciences, Poznan, Poland
  • Jan K. Nowak Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland
  • Edyta Madry Department of Physiology, Poznan University of Medical Sciences, Poznan, Poland
  • Katarzyna Katulska Department of General Radiology, Poznan University of Medical Sciences, Poznan, Poland
  • Sylwia Stezowska-Kubiak Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland
  • Jerzy Moczko Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznan, Poland
  • Agata Nowicka Department of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, Poznan, Poland
  • Aleksandra Lisowska Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland
  • Jaroslaw Walkowiak Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland

DOI:

https://doi.org/10.15403/jgld.2014.1121.251.chp

Keywords:

pancreatitis, fecal elastase, Wirsung duct, CFTR

Abstract

Background & Aims: Although indirect methods of assessment of the exocrine pancreatic function have become the standard of care in the monitoring of pancreatic status, it still remains a current clinical challenge. Our aim was to compare the width of the pancreatic duct in pancreatic insufficient (PI) and pancreatic sufficient (PS) cystic fibrosis (CF) patients using secretin-enhanced magnetic resonance cholangiopancreatography (SE-MRCP).

Methods: Thirty-seven CF patients were enrolled for this cross-sectional study, including 21 PI and 16 PS, all of whom underwent SE-MRCP. Measurement of the diameter of the pancreatic duct was performed in the head, body, and the tail of the pancreas at the baseline and after 1, 2, 3, 5, and 10 minutes after secretin administration.

Results: The diameter of the pancreatic duct in the head of the pancreas after 5 and 10 minutes of secretin injection was greater in PI than in PS patients (median = 2.0 mm [interquartile range: 1.6-3.0] vs. 2.0 mm [1.0-2.0] and 2.0 mm [1.4-2.0] vs 1.0 mm [1.0-2.0], p=0.047 and p=0.040, respectively). Areas under ROC curves for discriminating between PI and PS patients were 0.693 (95% CI 0.521-0.866) and 0.698 (95% CI 0.528-0.868), respectively. No other differences in the width of the duct were identified at the baseline or during SE-MRCP.

Conclusions: The measurement of the diameter of the pancreatic duct during secretin stimulation does not allow for differentiating between PS and PI status in CF patients.

Abbreviations: CF: cystic fibrosis; CFTR: cystic fibrosis transmembrane conductance regulator; ELISA: enzyme-linked immunosorbent assay; ERCP: endoscopic retrograde cholangiopancreatography; E1: elastase-1; MRI: magnetic resonance imaging; PI: pancreatic insufficient; PS: pancreatic sufficient; SCT gene: secretin gene; SE-MRCP: secretin-enhanced magnetic resonance cholangiopancreatography; T: tesla; TR: repetition time; TE: echo time.

Downloads

Published

2016-03-01

How to Cite

1.
Jonczyk-Potoczna K, Nowak JK, Madry E, Katulska K, Stezowska-Kubiak S, Moczko J, Nowicka A, Lisowska A, Walkowiak J. Secretin-enhanced Magnetic Resonance Cholangiopancreatography in Pancreatic Insufficient and Pancreatic Sufficient Cystic Fibrosis Patients. JGLD [Internet]. 2016 Mar. 1 [cited 2025 Jul. 1];25(1):57-62. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/1136

Issue

Vol. 25 No. 1: March 2016

Section

Original Article